UBS Asset Management Americas Inc. increased its position in Shire PLC (NASDAQ:SHPG) by 10.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 541,749 shares of the biopharmaceutical company’s stock after buying an additional 53,077 shares during the period. UBS Asset Management Americas Inc.’s holdings in Shire PLC were worth $105,023,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in SHPG. Quadrant Capital Group LLC increased its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the last quarter. Canal Insurance CO bought a new stake in Shire PLC during the second quarter worth $102,000. FTB Advisors Inc. increased its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. bought a new stake in Shire PLC during the second quarter worth $111,000. Finally, Ropes Wealth Advisors LLC bought a new stake in Shire PLC during the second quarter worth $114,000. 22.78% of the stock is owned by institutional investors and hedge funds.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.06% during trading on Monday, reaching $175.33. The company had a trading volume of 530,482 shares. Shire PLC has a 52-week low of $147.60 and a 52-week high of $215.05. The firm has a market capitalization of $52.22 billion, a P/E ratio of 36.44 and a beta of 1.46. The company has a 50 day moving average of $180.43 and a 200-day moving average of $187.45.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share for the quarter, missing analysts’ consensus estimates of $3.21 by $0.04. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. The company earned $3.45 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter last year, the company earned $3.24 earnings per share. The business’s revenue was up 108.6% on a year-over-year basis. Equities analysts expect that Shire PLC will post $12.93 earnings per share for the current year.
A number of analysts have recently weighed in on SHPG shares. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Jefferies Group reissued a “buy” rating and set a $262.00 price target on shares of Shire PLC in a research report on Tuesday, September 20th. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Leerink Swann restated a “buy” rating on shares of Shire PLC in a research note on Saturday, October 1st. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Shire PLC in a research note on Sunday, October 16th. Four investment analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $222.06.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.